Combined modality treatment for patients with stage IV melanoma: cyclophosphamide and a dendritic cell vaccine [melanoma vaccine] loaded with killed allogeneic melanoma cells.

Trial Profile

Combined modality treatment for patients with stage IV melanoma: cyclophosphamide and a dendritic cell vaccine [melanoma vaccine] loaded with killed allogeneic melanoma cells.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Jun 2013

At a glance

  • Drugs Cyclophosphamide (Primary) ; ODC 0501 (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Baylor Research Institute
  • Most Recent Events

    • 16 Sep 2010 Planned end date changed from 1 Mar 2012 to 1 Mar 2012 as reported by ClinicalTrials.gov.
    • 16 Sep 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 08 Jun 2010 Twenty-one patients have been accrued so far, of which 18 have received the vaccine, according to details reported at ASCO 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top